Skip to main content

Table 1 Clinical data of patients

From: Constitutive upregulation of the transforming growth factor-β pathway in rheumatoid arthritis synovial fibroblasts

Rheumatoid arthritis        
Patient Gender/age (years) Disease duration (years) RF ESR (mm/h) CRP (mg/ml) No. of ARA criteria Concurrent treatment
EB 73 M/68 8 + 90 48.1 6 MTX
EB 74 F/71 17 + 45 26.9 6 NSAIDs
EB 87 F/65 12 + 50 106.7 5 NSAIDs
EB 88 F/62 10 + 90 169.5 6 NSAIDs
EB 96 M/67 4 + 68 75.7 4 NSAIDs
EB 108 F/72 45 + 70 70.7 7 NSAIDs, steroids
EB 141 F/73 1 + 57 14.3 5 NSAIDs, steroids
Osteoarthritis        
EB 77 F/66 5 - 2 <5.0 0 None
EB 81 F/56 3 - 14 <5.0 0 None
EB 90 F/61 2 - 18 <5.0 0 None
EB 102 F/73 8 - 20 <5.0 0 NSAIDs
EB 115 F/56 3 - 11 8.2 0 NSAIDs
EB 118 M/72 2 - 4 9.3 0 NSAIDs
EB 135 M/57 4 - 12 <5.0 0 NSAIDs
EB 165 F/63 3 - 11 6.1 0 NSAIDs
EB 172 M/61 3 - 5 <5.0 0 NSAIDs
  1. ARA, American Rheumatism Association (now American College of Rheumatology); CRP, C-reactive protein (normal range <5 mg/l); ESR, erythrocyte sedimentation rate; F, female; M, male; MTX, methotrexate; NSAIDs, non steroidal anti-inflammatory drugs; RF, rheumatoid factor; -, negative; +, positive.